PrEP and Rapid Start: A Grand Round Series in the Underserved Southeast
Release date: July 8, 2021
Expiration date: July 8, 2022
Estimated time to complete activity: 1 hour
This activity is jointly provided by the Postgraduate Institute for Medicine and and the American Academy of HIV Medicine.
This activity is supported by an independent educational grant from Gilead Sciences.
This activity has been designed to meet the educational needs of physicians, physician assistants, nurse practitioners, registered nurses and pharmacists.
Erin McCaffrey Crespo, FNP-BC, AAHIVS
AIDS Healthcare Foundation Public Health Division
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008162-9999-21-2858-H02-P)
Type of Activity: Application
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Designated for 0.75 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
Fee Information: There is no fee for this educational activity.
Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period July 8, 2021 through July 8, 2022 participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please complete the evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 14577. Upon registering and completing the activity evaluation, your certificate will be made available immediately.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The planners, our presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with any ACCME-defined ineligible companies.
Hardware and Software Requirements
AAHIVM.org requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
If you have questions regarding the certification of this activity, please contact PIM via email at email@example.com.